Please login to the form below

Not currently logged in
Email:
Password:

Lidoderm

This page shows the latest Lidoderm news and features for those working in and with pharma, biotech and healthcare.

Endo builds pain management business

Endo builds pain management business

Endo also has an existing pain patch in the form of Lidoderm, which contains the active ingredient lidocaine.

Latest news

  • Endo agrees $1.6bn deal to buy Paladin Labs Endo agrees $1.6bn deal to buy Paladin Labs

    generic competition to Endo's Lidoderm (lidocaine) patch for post-shingles pain - and earnings per share (EPS) of $1.34, up from $1.28 a year earlier. ... Looking at the performance of Lidoderm, which fell 37 per cent, De Silva said that "prescription

  • Watson settles Lidoderm patent dispute with Endo Watson settles Lidoderm patent dispute with Endo

    Watson settles Lidoderm patent dispute with Endo. Watson can now bring its generic version of the post-shingles pain patch to US market two years early. ... Once another generic product is launched following the 2015 patent expiry, however, Watson will

  • Global survey shows neuropathic pain under-diagnosed and under-served

    Lidoderm is licensed to Endo for sale in the US and Versatis is licensed to Gruenenthal for the UK. ... For Endo in the US, Lidoderm racked up sales of USD 419 million in FY05.

More from news
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...
Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...

Infographics